Misplaced Pages

:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Tobramycin/dexamethasone: Difference between pages - Misplaced Pages

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Difference between pages)
Page 1
Page 2
Content deleted Content addedVisualWikitext
Revision as of 11:04, 20 February 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 477864441 of page Tobramycin/dexamethasone for the Chem/Drugbox validation project (updated: 'ChemSpiderID', 'KEGG', 'StdInChI', 'StdInChIKey').  Latest revision as of 00:11, 20 March 2024 edit Jusdafax (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers101,889 editsm Reverted edits by 105.71.135.50 (talk): not providing a reliable source (WP:CITE, WP:RS) (HG) (3.4.10)Tags: Huggle Rollback 
Line 1: Line 1:
{{Short description|Pharmaceutical preparation}}
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}}
{{Drugbox {{Drugbox
| Verifiedfields = changed
| verifiedrevid = 448047811 | verifiedrevid = 477865033
⚫ | type = combo


<!--Combo data--> <!--Combo data-->
⚫ | type = combo
| component1 = Tobramycin | component1 = Tobramycin
| class1 = ] | class1 = ]
Line 11: Line 12:


<!--Clinical data--> <!--Clinical data-->
| tradename = | tradename = Tobradex
| Drugs.com = {{drugs.com|ppa|tobramycin-and-dexamethasone}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C | pregnancy_US = C
| pregnancy_US_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Dexamethasone / tobramycin ophthalmic Use During Pregnancy | website=Drugs.com | date=28 November 2018 | url=https://www.drugs.com/pregnancy/dexamethasone-tobramycin-ophthalmic.html | access-date=13 September 2020}}</ref>
| pregnancy_category = | pregnancy_category =
⚫ | routes_of_administration = ], ]
⚫ | ATCvet =
| ATC_prefix = S01
⚫ | ATC_suffix = CA01

| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> | legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Rx-only | legal_US = Rx-only
| legal_US_comment = <ref name="Tobradex ointment FDA label" /><ref name="Tobradex drops FDA label" /><ref name="Tobradex ST FDA label" />
| legal_status = | legal_status =
⚫ | routes_of_administration = ]


<!--Identifiers--> <!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 32986-56-4 | CAS_number = 32986-56-4
| CAS_number2_Ref = {{cascite|correct|CAS}}
⚫ | ATCvet =
| ATC_prefix = S01 | CAS_number2 = 50-02-2
⚫ | ATC_suffix = CA01
⚫ | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
⚫ | ChemSpiderID = 33377
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NLVFBUXFDBBNBW-PBSUHMDJSA-N
⚫ | ChEMBL = 1747
⚫ | ChEBI = 28864
| KEGG = <!-- blanked - oldvalue: D00063 -->
| PubChem = | PubChem =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00684 | DrugBank = DB00684
⚫ | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
⚫ | ChemSpiderID = 10123949
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = VZ8RRZ51VK
| UNII2_Ref = {{fdacite|correct|FDA}}
| UNII2 = 7S5I7G3JQL
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D11178
| ChEBI_Ref = {{ebicite|correct|EBI}}
⚫ | ChEBI = 28864
| ChEMBL_Ref = {{ebicite|correct|EBI}}
⚫ | ChEMBL = 1747
}} }}

'''Tobramycin/dexamethasone''', sold under the brand name '''Tobradex''', is a fixed-dose ] in the form of ] and eye ], marketed by ].<ref name="Tobradex ointment FDA label" /><ref name="Tobradex drops FDA label" /><ref name="Tobradex ST FDA label" /> The active ingredients are ] (an ]) and ] (a ]).<ref name="Tobradex drops FDA label" /> It is prescribed for the treatment of ] in combination with bacterial infections.<ref name="Tobradex drops FDA label" />

== Contraindications ==
It is contraindicated with ] and other ] eye infections. Other contraindications include ] and ]l infections because tobramycin is inactive against those, and the corticoid acts as an ] agent, preventing the body's immune system from dealing with the infection. The drops are also contraindicated in patients with ]l lesions.<ref name="AustriaCodex">{{cite book|title=Austria-Codex|at=Tobradex-Augentropfen| veditors = Haberfeld H |publisher=Österreichischer Apothekerverlag|location=Vienna|year=2009|edition=2009/2010|isbn=978-3-85200-196-8|language=German}}</ref><ref name="Tobradex ointment FDA label">{{cite web | title=Tobradex- tobramycin and dexamethasone ointment | website=DailyMed | date=24 April 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5538d748-215c-4e3e-b940-ac9baf07d8a1 | access-date=24 September 2020}}</ref><ref name="Tobradex drops FDA label">{{cite web | title=Tobradex- tobramycin and dexamethasone suspension/ drops | website=DailyMed | date=24 April 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22b59456-d26a-4f23-b052-3d73e00181eb | access-date=24 September 2020}}</ref><ref name="Tobradex ST FDA label">{{cite web | title=Tobradex ST- tobramycin / dexamethasone suspension/ drops | website=DailyMed | date=9 September 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1d48422-8cfc-4e9e-a7f8-56c274d8eb83 | access-date=24 September 2020}}</ref>

== Side effects ==
Similarly to other corticosteroid eye drops, ]s include ] and, especially after long-term use, secondary eye infections, ] (clouding of the eye lens) and increased ], leading to ]. Consequently, the drug should not be applied longer than 24 days<ref name="AustriaCodex"/><ref name="ÖAZ">{{cite journal | vauthors = Faschinger C | date = 3 January 2011 | journal = Österreichische Apothekerzeitung | title = TobraDex | issue = 1/2011 | pages = 13 | language = German }}</ref><ref name="Arzneistoff-Profile">{{cite book|title=Arzneistoff-Profile| veditors = Dinnendahl V, Fricke U |publisher=Govi Pharmazeutischer Verlag|location=Eschborn, Germany|year=2010|edition=23|volume=2|isbn=978-3-7741-9846-3|language=German}}
</ref> without further medical evaluation.<ref name="Tobradex drops FDA label" /><ref name="Tobradex ST FDA label" />

==Interactions==
] eye drops potentiate the risk of increased intraocular pressure. Systemic ]s increase toxicity for ears, nerves and kidney.<ref name="AustriaCodex" />

== Brand names ==
Tobrason is a brand name in Jordan.<ref>{{cite web | title = Jordanian Food and Drug Administration | url = http://www.jfda.jo/}}</ref>{{failed verification|date=September 2020}}

==References==
{{reflist}}

== External links ==
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/dexamethasone%20mixture%20with%20tobramycin | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Dexamethasone mixture with tobramycin }}

{{AminoglycosideAntiBiotics}}
{{Corticosteroids}}
{{Portal bar | Medicine}}

{{DEFAULTSORT:Tobramycin Dexamethasone}}
]
]
]
]